
New Paybis OTC Desk And Wallets To Simplify Crypto Payments
London, UK, June 16, 2025 (GLOBE NEWSWIRE) -- Paybis, a global fiat-to-crypto gateway, is rolling out a secure and efficient OTC desk and crypto wallet to meet growing business demand for digital assets.
With crypto acceptance growing close to 50% year-on-year among merchants, the OTC desk simplifies on- and off-ramping digital assets for businesses. An increasing number of enterprises are holding Bitcoin, Ethereum, and stablecoins on balance sheets for treasury purposes, with fintechs and startups using the secure Paybis business wallet to store, swap, send, receive and pay in cryptocurrency.
Both OTC desk and the wallet ensure seamless transactions at competitive fees, featuring a solution available around the world, complete with 24/7 customer support.
Responding to the crypto custody provider market nearly doubling (84%) in the next 5 years, Paybis has developed a full service platform to remove complexity from the process and give companies a smooth, secure experience.
From settling invoices to managing treasury assets, the tools are built to handle real-world business needs without the usual crypto learning curve.
Paybis Co-Founder and CBDO, Konstantins Vasilenko, commented: '88% of merchants report increased revenue after accepting crypto payments. Our OTC and business wallet solutions are helping businesses attract more web2 customers and tokenize their assets securely.'
Paybis is licensed both in the EU (VASP) and the US (FinCEN) and tackles critical issues present in today's crypto market. Some of these issues include complex UI, slow and low-quality customer support, slow onboarding and compliance times, weak security, limited geographic coverage, and the lack of support for fiat currencies.
The solutions simplify processes like onboarding, KYC, and transaction handling and also support local payment rails in over 25 fiat currencies with no FX fees. They include tiered pricing to accommodate businesses at every stage of growth.
A key feature is Paybis' streamlined onboarding, which drastically cuts down wait times. Thanks to an entirely in-house, end-to-end verification process, businesses can get started in under 24 hours — without the endless back-and-forth often seen in compliance workflows. Once onboarded, clients have full, unrestricted access to their funds, including instant deposits and withdrawals, giving them total control over how and when they move money.
The platform also supports a wide range of fiat currencies and payment methods, helping businesses tap into local markets while operating globally. With fast settlement, competitive rates, and an intuitive dashboard, Paybis' new B2B suite makes integrating crypto into operations less of a technical headache — and more of a strategic advantage.
About Paybis
Paybis is a global crypto platform with 11 years of experience, providing solutions for both individuals and businesses to buy, sell, and transfer digital currencies. Our services range from on/off-ramp solutions to OTC desk, B2B payments, and more. Operating globally with millions of customers across the US, UK, and Europe, we ensure full compliance with local regulations. Trusted by the world's leading businesses over 5 million users, Paybis makes crypto transactions effortless, secure, and accessible worldwide.
The company also operates in 141 countries globally, including 38 US states, providing crypto transaction services to the majority of the world's population. Its reach extends over five continents, connecting diverse regions, enabling financial inclusion to over 1.4 billion unbanked people, and offering an easy-to-use solution that outperforms traditional banking solutions, all while maintaining regulatory compliance in each jurisdiction.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
41 minutes ago
- CTV News
European Union leaders say Canada will sign a defence procurement pact this month
European Commission President Ursula von der Leyen and European Council President Antonio Costa, left, attend a United Kingdom and European Union summit at Lancaster House in London on Monday, May 19, 2025. (Henry Nicholls/Pool Photo via AP) KANANASKIS — European Union officials say Canada is likely to sign a defence procurement agreement with the continent when Prime Minister Mark Carney goes to Brussels later this month. Carney is set to visit Brussels on June 23 for the Canada-EU summit, where he will meet with European Commission President Ursula von der Leyen and European Council President António Costa. Attending the G7 summit in Alberta today, both EU leaders say Canada's involvement in what they call Europe's 'rapidly evolving defence architecture' is set to deepen. Von der Leyen says Canada will sign a security and defence partnership with the EU which will allow it to join a European loan program for joint defence projects. The 150-billion euro program is called Security Action for Europe, or SAFE, and is part of the ReArm Europe initiative that Carney says he wants Canada to join. Von der Leyen says the SAFE program can be joined by Europe's 'very close allies, friends and partners' and the deal this month will allow for negotiations on bringing Canada into the program. This report by The Canadian Press was first published June 16, 2025. Dylan Robertson, The Canadian Press


CTV News
an hour ago
- CTV News
OPEC expects solid second-half of 2025 for world economy, trims 2026 supply
The logo of the Organization of the Petroleum Exporting Countries is seen outside of OPEC's headquarters in Vienna, Austria, on March 3, 2022. (AP Photo/Lisa Leutner, File) LONDON — OPEC said on Monday it expected the global economy to remain resilient in the second half of this year and trimmed its forecast for growth in oil supply from the United States and other producers outside the wider OPEC+ group in 2026. In a monthly report which did not mention the Israel-Iran conflict, the Organization of the Petroleum Exporting Countries also left its forecasts for global oil demand growth unchanged in 2025 and 2026, after reductions in April. It said the economic outlook was robust despite trade concerns. A solid economy shrugging off trade conflicts and a slowdown in supply growth outside OPEC+ - which groups OPEC plus Russia and other allies - would make it easier for OPEC+ to balance the oil market. Rapid growth from U.S. shale and from other countries has weighed on prices in recent years. 'The global economy has outperformed expectations so far in the first half of 2025,' OPEC said in the report. 'This strong base from the first half of 2025 is anticipated to provide support and sufficient momentum into a sound second half of 2025. However, the growth trend is expected to moderate slightly on a quarterly basis.' Oil jumped on Friday nearing US$80 a barrel after air strikes by Israel and Iran raised concern about regional supply, having in recent weeks come under pressure from OPEC+'s output hikes and from U.S. President Donald Trump's tariffs. Sources have told Reuters that behind OPEC+'s plan to ramp up oil output more rapidly in May, June and July than first planned is also the objective of taking on U.S. shale production to win back market share. In the report, OPEC said supply from countries outside the Declaration of Cooperation - the formal name for OPEC+ - will rise by about 730,000 barrels per day in 2026, down 70,000 bpd from last month's forecast. OPEC now expects U.S. output of tight oil, another term for shale, to hold steady next year at 9.05 million barrels per day. Last month, it expected small growth year on year and in January had forecast output in 2026 would reach 9.28 million bpd. 'The 2026 forecast assumes sustained capital discipline, further drilling and completion efficiency gains, weaker momentum in drilling activities and increased associated gas production in key shale oil regions,' OPEC said of tight oil. Kazakhstan's output falls OPEC's report also found production by OPEC+ rose in May by 180,000 bpd to 41.23 million bpd, less than the 411,000 bpd hike called for by the group's increase in its May quotas. The actual hike was smaller than the headline increase in quotas partly because some nations, such as Iraq, cut output as part of a pledge to make further reductions for earlier pumping above targets. Output in Kazakhstan, which is under pressure to boost compliance with OPEC+ quotas, also declined, falling by 21,000 bpd in May to 1.803 million bpd, still above its quota. --- Alex Lawler, Reuters Additional reporting by Olesya Astakhova and Vladimir Soldatkin, editing by Emelia Sithole-Matarise


Globe and Mail
an hour ago
- Globe and Mail
Can J&J's Innovative Medicines Unit Sustain Growth Amid Stelara LOE?
Johnson & Johnson JNJ has one of the most diverse revenue streams in the industry within the pharmaceutical division called Innovative Medicine. Under this segment, J&J markets several multi-million-dollar drugs covering a broad range of areas such as neuroscience, cardiovascular and metabolism, immunology, oncology, pulmonary hypertension and infectious diseases. J&J's Innovative Medicine unit is showing a growth trend. The segment's sales rose 4.4% in the first quarter of 2025 on an organic basis despite the loss of exclusivity (LOE) for its multi-billion-dollar product, Stelara, and the negative impact of the Part D redesign. A biosimilar version of J&J's multi-billion-dollar immunology drug, Stelara, was launched in certain European markets for some indications in July 2024. Several biosimilar versions of Stelara are expected to be launched in the United States in 2025, according to patent settlements and license agreements. Amgen AMGN launched the first Stelara biosimilar, Wezlana, in January 2025, while Teva launched Selarsdi in February 2025. Stelara biosimilar competition is expected to accelerate throughout 2025 as the number of biosimilar entrants increases. Stelara sales are expected to come down from almost $11 billion in 2023 to around $2.9 billion in 2027, per our estimates. However, despite Stelara LOE, J&J expects growth in the Innovative Medicine segment in 2025 to be driven by its key products such as Darzalex, Tremfya, Spravato and Erleada as well as new cancer drugs like Carvykti, Tecvayli and Talvey, and new indications for Tremfya and Rybrevant. J&J expects to generate more than $57 billion in sales in the Innovative Medicine segment in 2025. It expects the Innovative Medicine business to grow 5-7% from 2025 to 2030. J&J Key Competitors Immunology and oncology are J&J's key areas. Other large drugmakers holding a strong presence in the oncology market are Novartis, AstraZeneca, AbbVie ABBV, Merck, Bristol-Myers, Roche and Pfizer PFE. In immunology, AbbVie, Amgen, Sanofi, AstraZeneca and Pfizer hold a strong position. JNJ's Price Performance, Valuation and Estimates J&J's shares have outperformed the industry year to date. The stock has risen 10.4% in the year-to-date period compared with an increase of 4.0% for the industry. From a valuation standpoint, J&J is reasonably priced. Going by the price/earnings ratio, the company's shares currently trade at 14.58 forward earnings, slightly lower than 15.65 for the industry. The stock is also trading below its five-year mean of 15.76. The stock is cheaper than some other drugmakers like AbbVie, Lilly and Novo Nordisk. The Zacks Consensus Estimate for 2025 earnings has risen from $10.51 per share to $10.60 over the past 60 days, while that for 2026 has declined from $10.99 to $10.98 over the same timeframe. J&J has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report